SK Biopharmaceuticals Co., Ltd.
326030
Rank in Stocks
#4054
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Share Price
$51.52
Last synced: 2026-10-20
Market Cap
$4.03B
Change (1 day)
-2.23%
Change (1 year)
-31.13%
Country
KR
Trade SK Biopharmaceuticals Co., Ltd. (326030)
Category
Healthcare
Number of shares outstanding for SK Biopharmaceuticals Co., Ltd. (326030)
Number of shares outstanding as of June 2026: 78.31M
According to SK Biopharmaceuticals Co., Ltd. latest financial reports and stock price the company's current number of shares outstanding is 78.31M. At the end of December 2024 the company had 78.31M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for SK Biopharmaceuticals Co., Ltd. (326030) from 2011 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 78.31M | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 78.31M | 0.00% |
| 2023 | 78.31M | 0.00% |
| 2022 | 78.31M | 0.00% |
| 2021 | 78.31M | 9.12% |
| 2020 | 71.77M | 10.41% |
| 2019 | 65.00M | 4.44% |
| 2018 | 62.23M | 24.47% |
| 2017 | 50.00M | -0.04% |
| 2016 | 50.02M | 0.04% |
| 2015 | 50.00M | 1.08% |
| 2014 | 49.46M | 23.66% |
| 2013 | 40.00M | -0.03% |
| 2012 | 40.01M | 0.11% |
| 2011 | 39.97M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 224.21% |
US
|
|
| 396.00M | 405.66% |
US
|
|
| 478.91M | 511.54% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.59% |
NL
|
